Top

Published in:

02-03-2024 | Polycystic Kidney Disease | Research Letter

Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study

Authors: Gianni Carraro, Valentina Di Vico, Loris Martinetti, Elisabetta Bettin, Martina Cacciapuoti, Lucia Federica Stefanelli, Laura Gobbi, Federico Nalesso, Francesca Katiana Martino, Lorenzo A. Calò

Published in: Clinical Drug Investigation | Issue 4/2024

Excerpt

Autosomal polycystic kidney disease (APKD) is the most common monogenic hereditary kidney disease, but 10% of cases are de novo mutations. About 70% of autosomal dominant polycystic kidney disease (ADPKD) patients reach end-stage renal disease, representing about 10% of people on dialysis [1, 2]. The growth of renal cysts is due to increased cell proliferation, linked to PKD1 or PKD2 mutation that causes the accumulation of cyclic adenosine monophosphate (cAMP). cAMP leads to cystogenesis activating cellular proliferation and secretion [3]. Tolvaptan, an antagonist of vasopressin's V2 receptor, has demonstrated its efficacy in interfering with cAMP accumulation, slowing total kidney volume (TKV), and is now a valuable option for treating ADPKD patients [4]. …

Perumareddi P, Trelka DP. autosomal dominant polycystic kidney disease. Prim Care. 2020;47:673–89.CrossRefPubMed

Corradi V, Giuliani A, Gastaldon F, de Cal M, Mancini B, Montaldi A, et al. Genetics and autosomal dominant polycystic kidney disease progression. Contrib Nephrol. 2017;190:117–23.CrossRefPubMed

Nobakht N, Hanna RM, Al-Baghdadi M, Ameen KM, Arman F, Nobahkt E, et al. Advances in autosomal dominant polycystic kidney disease: a clinical review. Kidney Med. 2020;2:196–208.CrossRefPubMedPubMedCentral

Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recom-mendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;3:337–48.CrossRef

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33:477–89.CrossRefPubMed

Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018;11:41–51.CrossRefPubMedPubMedCentral

Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437–40.CrossRefPubMedPubMedCentral

Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31:180–91.CrossRefPubMed

OpenEpi (Open Source Epidemiologic Statistics for Public Health). https://www.openepi.com/SampleSize/SSMean.htm. Accessed 20 Feb 2024.

10.

Anderegg MA, Dhayat NA, Sommer G, Semmo M, Huynh-Do U, Vogt B, et al. Quality of Life in autosomal dominant polycystic kidney disease patients treated with tolvaptan. Kidney Med. 2020;2:162–71.CrossRefPubMedPubMedCentral

11.

Simms RJ, Thong KM, Dworschak GC, Ong AC. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016;31:1130–40.CrossRefPubMed

Title: Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study
Authors: Gianni Carraro
Valentina Di Vico
Loris Martinetti
Elisabetta Bettin
Martina Cacciapuoti
Lucia Federica Stefanelli
Laura Gobbi
Federico Nalesso
Francesca Katiana Martino
Lorenzo A. Calò
Publication date: 02-03-2024
Publisher: Springer International Publishing
Keyword: Polycystic Kidney Disease
Published in: Clinical Drug Investigation / Issue 4/2024
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-024-01350-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2024

Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan

Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far